Preparent Standard Panel
|
|
- Everett Cummings
- 5 years ago
- Views:
Transcription
1 Preparent Standard Panel Disorder Gene Variants Ethnicity Alpha-thalassemia HBA1 HBA2 -alpha3.7, -alpha4.2, -alpha20.5, --SEA, --MED, --FIL, --THAI Mediterranean 1 in 20 1 in in 291 African American 1 in in 4,991 Beta-thalassemia HBB 118C>T, 126_129delCTTT, 135delC, -138C>T, 22_24delGAG, 25_26delAA, 27dupG, 315+1G>A, 316-2A>C, 316-2A>G, 47G>A, 51delC, 52A>T, 59A>G, 75T>A, -78A>G/-28A>G, -79A>G/-29A>G, 93-1G>A, 93-21G>A Mediterranean South Southeast East 1 in 20 1 in 20 1 in 50 80% 29% 69% 71% 74% 1 in 96 1 in 28 1 in 95 1 in 112 African American 1 in 50 1 in 75 1 in 80 37% 85% 80% 1 in 79 1 in in 396 Bloom syndrome BLM 2281Del6/Ins7, 2407dupT Ashkenazi Jewish 1 in in 9,901 Canavan disease ASPA IVS2-2A>G, p.a305e, p.e285a, p.y231x, p.y288c Ashkenazi Jewish 1 in 41 98% 1 in 2,001 1 in % 1 in 328 Congenital amegakaryocytic thrombocytopenia MPL IVS1+2T>A Ashkenazi Jewish 1 in 75 1 in 7,401 Cystic fibrosis (600 mutations) CFTR R347P; Y122X; 852del22; S549R; S1255X; L1077P; G->A; G->A; 711+1G->T; G>A; 4016insT; Q1313X; 4209TGTT>AA; 4382delA; 2143delT; L1065P; R1066C; R1066H; R117C; L467P; 1548delG; S489X; S492F; 3821delT; Q179K; M1101K; E1104X; Y1092X; R117H; PolyT 5T/7T/9T; 574delA; 663delT; G178R; 711+3A>G; 711+5G>A; 712-1G>T; H199Y; P205S; L206W; Q220X; R334W; 935delA; A455E; 1078delT; G330X; I336K; T338I; S341P; 1154insTC; R347H; R352Q; 1213delT; G>A; 1259insA; W401X; W401X; G>A; 1461ins4; G>A; F508C; 1677delTA; V520F; G542X; 621+1G->T; [delta]f311; [delta]f508; S466X; G551D; G->A; R553X; R560T; S549N; Q552X; S549R; A559T; R560K; kbA->G; G->A; Y569D; I507V; E585X; G->C; A>G; 2184delA; 2184insA; R709X; K710X; 2307insA; L732X; 2347delG; G>A; R764X; 2585delT; E822X; G>A; E831X; W846X; R851X; 2711delT; Q890X; L927P; S945L; 3007delG; G970R; 3120G>A; Ashkenazi Jewish African American 1 in 24 1 in 25 1 in 58 1 in 61 1 in % 82% 56% -- 1 in 2,301 1 in in in in S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 1 of 8
2 3121-1G->A; 3171delC; 3199del6; G->A; A->G; 394delTT ; D1152H; R1158X; R1162X; 3659delC; W1282X; S1196X; 3791delC; N1303K; N1303K; W1204X; W1204X; S1255X; G1244E; 3876delA; S1251N; 3905insT; kbC->T; CFTRdele22.23; 444delA; 457TAT->G; S466X; Y1092X; [delta]i507; 2183delAA>G; M1V; G85E; Q39X; 406-1G->A; E60X; P67L; R75X; 405+1G>A; E92X; E92K; Q98X; D110H; W1089X; CFTRdele2.3; 1949del84; Q493X; G->A; I506V(1648A/G); G->T; W361X; 681delC; 1367delC; 1367del5; 1460delAT; 1471delA; 1353_1354insT; 1504delG; 1540del10; 1565 del CA; 1571delG; 1576insT; 1469delT; 1601delTC; 1660delG; 1742delAC; 1749insTA; 1774delCT; Y325X; R792X; L558X; G1003X; Y161X; 412del7- >TA; H1054D; G1061R; 3532AC- >GTA; F1074L; Y28X; R29X; E33X; 3960_3961delA; L34X; S35X; S35X; K114X; W277X; G404X; W882X; S912X; S1206X(C>A); S1206X (C>G); L1254X; W1274X; Q1281X; Q1291X; Y1307X; E1308X; W1310X; W1316X; E1371X; R532X; E535X; M1L; K536X; A46D; 297-1G>A; G551S; E543X; G545X; R555X; L558X; Y563X; K564X; L90X; L94X; L101X; G366X; K370X; L375X; Q376X; K377X; Q378X; Y380X; K381X; L383X; E384X; Y385X; Y385X; L387X; L387X; E391X; E395X; E402X; E403X; E407X; L408X; L408X; E410X; K411X; K447X; E449X; R450X; G451X; Q452X; L453X; L454X; G458X; G461X; G473X; E476X; S478X; S478X; K481X; K483X; R487X; C491X; K503X; Y512X; E514X; R516X; 547insTA; 556delA ; 557delT; 565delC; 605insT; 657delA; K442X; 1782delA; Q353X; 2948AT- >C; 3079delTT; 3293delA; 3126del4; 3132delTG; 3171insC; 3173delAC; 3200_3204delTAGTG; 3238delA; 3180delA; 3320ins5; 3359delCT; 3263dupA; 3396delC; 3419delT; 3423delC; 3425delG; 3447delG; 3855delC; 3577delT; 3617delGA; 3622insT; 3629delT; 3662delA; 3667ins4; 3670delA; 3724delG; 3737delA; 3750delAG; 3755delG; 3789insA; 3708delT; 3878delG; 3898insC; 3906insG; 3944delGT; 3835_3836delTT; 4006delA; 4010del4; 4015delA; 4022insT; 3908dupA; 4040delA; 4048insCC; 4089ins4; 4203TAG->AA; 4218insT; Q2X (together with R3W); S4X; E7X; K14X; G27X; Q30X; Y38X; W57X(TAG); W57X(TGA); W79X; L88X(T- >A); L88X(T- >G); L101X; G103X; Y109X; L127X; L159X; E193X; Q207X; W216X; L218X; C225X; 717delG; Y247X; 825C>G; Q290X; Y304X; L320X; W356X; 1086T>A; 1114C>T; E379X; Q414X; S434X; E479X; G486X; E504X; G550X; L568X; 5230 S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 2 of 8
3 Y569X; G576X; Q634X; S776X; Q781X; R785X; Q637X; E656X; E664X; G673X; W679X; Q685X; K688X; Q814X; E823X; E1418X; 360delT; 234delC; insT; 264_268delATATT ; Y913X; K946X; K978X; L1059X; W1063X; Q1071X; M1T; S1255P; G1349D; 435insA; 441delA; 451del8; 458delAT; 460delG; 489delC; 519delT; 525delT; 405_406dupAC; 541del4; 541delC; 546insCTA; 547insGA; 675del4; 1497delGG; 2406delCC; 2409delC; 2456delAC; 2512delG; 2522insC; 2556insAT; 2566insT; 2876delC; 3028delA; 3041delG; 3056delGA; 3732delA; E827X; K830X; E474X; W846X (2670TGG>TGA); Y849X; E51X; R104X; 733delG; 650_659delAGTTGTTACA ; 714delT; 874Ins TACA; 905delG; insA; 991del5; 1013delAA; 1058delC; 1112delT ; 1119delA; 1138insG; 1150delA; 1161insG; 1161delC; M1K; 1215delG; 1111dupA; 1283delA; 1289insTA; 1291delTT; T388X; 1309delG; 1227delT; 1366delG; K52X; E54X; E56X; C276X; R59X; S63X; K64X; K65X; K68X; C76X; W79X; R80X; Y84X; G85X; Y89X; L90X; 1086T>G; L219X; E267X; 2044delA; E286X; S341X; R1128X; K413X; C831X; L571X; Y577X; Y577X; L581X; L581X; E588X; E838X; 1199delG; L320X; 1323insA; L570X; L570X; 1813insC; L571X; K857X; L859X; L859X; W865X; E883X; G885X; G>C; 1824delA; 2694delT; 2055del9->A; A561E; G>C; 3100insA; E115X; E116X; L127X; C128X; G149X; Y161X; K162X; K163X; K174X; G178X; Q179X; K190X; G194X; L197X; L206X; E217X; L219X; G226X; Q237X; R242X; K246X; Y247X; K254X; E257X; R258X; S263X; S263X; E264X; Q270X; K273X; L288X; L288X; R289X; E292X; K294X; K298X; Y301X; R303X; S308X; S313X; K329X; C343X; W356X; Q359X; W1098X(TAG); W1098X(TGA); R1102X; K1177X; Y1182X; Q1186X; 1645_1648delAGTG; Y852X; L867X; 4272C>A; 211delG; 237insA; 241delAT; 284delA; 295ins8 ; 300delA; 306delTAGA; 306insA; 198_202delTCCTA; 347delC; insT; 1784delG; 1787delA; 1660_1661insA; 1802delC; 1806delA; 1833delT; 1845delAG/1846delGA; 1870delG; 1874insT; 2051delTT; 2113delA; 2116delCTAA; 2141insA; 2176insC; 2185insC; 2603delT; 2634delT; 2634insT; 2640delT; 2554dupT; 2566_2567insT; 2721del11; 2723delTT; 2732insA; 2734G- >AT; 2747delC; 2766del8 ; 2686_2687insT; 2705delG; 2896insAG; 2907delTT; 2909delT; 2789delG; 2803_2813delCTACCACTGGT; 2942insT; D110N; D110Y; G480C; Q493delCA; Q493P; Q493R; I506T; 5230 S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 3 of 8
4 1898+5G->T; D614G; R1162L; 3667del4; I1234V; S1235R; Q1238X; A->G; D1270N; N1303I; 710_711+ 5del7; G622D; 2043delG; del13insAGAAA; 2108delA; R668C; F1052V; G1069R; R1070W; R1070Q; H139L; H139R; I148T; L227R; 936delTA; R347L; Q359K; T360K; S364P; 1288insTA; C524X; Q525X; L558S; Y569H; P574H; G576A; D579G; V754M; insA; 2869insG; S977F; L997F; 3130delA; I1027T; 2183delAA; 405+3A>C; G85V; 3765A>G; R31C; R31L; 296(+2)T>A; 296(+2)T>C; 296(+2)T>G; R74W; R75Q; 708delT Dihydrolipoamide dehydrogenase deficiency DLD p.g229c, p.y35x Ashkenazi Jewish 1 in in 2,121 Familial dysautonomia IKBKAP IVS20(+6)T>C, p.r696p Ashkenazi Jewish 1 in 31 1 in 3,001 Familial hyperinsulinism, ABCC8-related ABCC8 c g>a, delf1388 Ashkenazi Jewish 1 in 52 1 in % 1 in 1,701 1 in 184 Fanconi anemia, type C FANCC c.322delg, IVS4(+4)A>T, p.r548x Ashkenazi Jewish 1 in 89 1 in 8,801 1 in in 878 Fragile X syndrome* FMR1 CGG repeat analysis 1 in Gaucher disease GBA IVS2+1G>A, p.d409h, p.d409v, p.l444p, p.l47x, p.n370s, p.r496h, p.v394l Ashkenazi Jewish 1 in 18 1 in % 1 in in 279 Glycogen storage disease, type la G6PC p.q347x, p.r83c Ashkenazi Jewish 1 in 71 1 in 7,001 1 in % 1 in 321 Hemoglobinopathy evaluation N/A N/A Hemoglobinopathy, Hb C HBB 19G>A African American 1 in 15 1 in 46 1 in 68 1 in 1,401 1 in 4,501 1 in 6,701 Indian 1 in in in 11,801 1 in 16,901 1 in 25,401 Southeast 1 in in in in 29,101 1 in 66,101 1 in 79,001 1 in 49,901 Hemoglobinopathy, Hb D HBB 364G>C African American 1 in 15 1 in 46 1 in 68 1 in 1,401 1 in 4,501 1 in 6,701 1 in in 11,801 1 in 16, S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 4 of 8
5 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Hb E HBB 79G>A African American 1 in 15 1 in 46 1 in 1,401 1 in 4,501 1 in 68 1 in in 6,701 1 in 11,801 1 in 16,901 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Hb O HBB 364G>A African American 1 in 15 1 in 46 1 in 1,401 1 in 4,501 1 in 68 1 in in 6,701 1 in 11,801 1 in 16,901 Indian 1 in in in in 25,401 1 in 29,101 1 in 66,101 Southeast 1 in in 79,001 1 in 49,901 Hemoglobinopathy, Sickle cell anemia (HbS) HBB 20A>T African American 1 in 14 1 in in 1,301 1 in 17,501 1 in in in in 18,201 1 in 35,901 1 in 62,401 Indian 1 in in in 1,336 1 in 72,401 1 in 77,401 1 in 133,501 Southeast 1 in 4,004 1 in 25 1 in 400,301 1 in 2,401 Joubert syndrome 2 TMEM216 p.r12l Ashkenazi Jewish 1 in 92 1 in 1,821 Maple syrup urine disease, type IA BCKDHA p.y438n Ashkenazi Jewish Mennonite 1 in 81 1 in 10 1 in in 8,001 1 in in S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 5 of 8
6 Maple syrup urine disease, type IB BCKDHB p.e372x, p.g278s, p.r183p Ashkenazi Jewish 1 in 81 1 in in 8,001 1 in 267 Mucolipidosis type IV MCOLN1 del6.4kb, IVS3-2A>G Ashkenazi Jewish 1 in in 2,521 Nemaline myopathy 2 NEB p.r2478_d2512del Ashkenazi Jewish 1 in in 10,701 Niemann-Pick disease, type A and B SMPD1 delr608, fs330, p.l302p, p.r496l Ashkenazi Jewish 1 in 90 1 in % 20% 1 in 2,968 1 in 312 Northern African 1 in % 1 in 1,916 Spinal muscular atrophy SMN1 SMN2 Copy number analysis Two Copies SMN1 Three copies SMN1 Ashkenazi Jewish 1 in 35 1 in 41 1 in 53 93% 1 in in 3,500 1 in in 4,000 1 in in 5,000 African American 1 in 66 1 in in 50 71% 91% -- 1 in in 3,000 1 in 1,061 1 in 11, Tay-Sachs disease (DNA) HEXA 1278+TATC, IVS12+1G>C, IVS7+1G>A, IVS9+1G>A, p.g269s, p.r178h, p.r247w, p.r249w, del7.6kb Ashkenazi Jewish French Canadian/Cajun 1 in % 82% 59% 1 in in in 730 Tay-Sachs disease (hexosaminidase A) N/A N/A Ashkenazi Jewish French Canadian/Cajun 1 in 31 98% 98% 1 in 1,493 1 in 1, % 1 in 14,948 Usher syndrome, type IF PCDH15 p.r245x Ashkenazi Jewish 1 in in % 1 in in 439 Usher syndrome, type III CLRN1 528T>G, p.n48k Ashkenazi Jewish 1 in in 2,381 Walker-Warburg syndrome FKTN p.f390x Ashkenazi Jewish 1 in in 2,981 *X-linked disorder; carrier frequency and residual risk provided apply to females only. Additional variants evaluated as of April 1, S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 6 of 8
7 Preparent Standard Panel Test References 1. Alter BP, Kupfer G. Fanconi Anemia. GeneReviews. Last updated February 7, Available at: 2. American College of Medical Genetics and Genomics (ACMG) Practice Guidelines. screening in individuals of Ashkenazi Jewish descent. Genet Med. 2008;10(1): American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 318. Screening for Tay-Sachs Disease. Obstet Gyn Oct;106(4): American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 442. Preconception and Prenatal Screening for Genetic Diseases in Individuals of Eastern European Jewish Descent. Obstet Gyn Oct;114(4): American College of Obstetrics and Gynecology Committee Opinion Number 486. Update on Screening for Cystic Fibrosis. Obstet Gyn Apr;117(4): American College of Obstetrics and Gynecology Committee Opinion Number 78. Hemoglobinopathies in pregnancy. Obstet Gyn Jan;109(1): Anderson SL, Ekstein J, Donnelly MC, et al. Nemaline myopathy in the Ashkenazi Jewish population is caused by a deletion in the nebulin gene. Hum Genet Aug;115(3): [PMID: ] 8. Axelrod FB, Gold-Von Simson G. Familial dysautonomia. Orphanet. Last updated November Available at: http// php?lng=en&data_id= Bali DS, Chen Y, Goldstein JL. Glycogen Storage Disease Type 1. GeneReviews. Last updated September 19, Available at: Bender MA, Seibel GD. Sickle Cell Disease. GeneReviews. Last updated October 23, Available at: Blanchet C, Hamel C. Usher Syndrome. Orphanet. Last updated February Available at Brancati F, Dallapiccola B, Valente EM. Orphanet. Joubert syndrome. Last updated July Available at: http// Disease_Search.php?lng=EN&data_id= Caillaud C. Mucolipidosis Type 4. Orphanet. Last updated June Available at: http// 14. Cao A, Galanello R, Origa R. Beta-Thalassemia. GeneReviews. Last updated May 14, Available at: Chang W, Winder TL, LeDuc CA, et al. Founder fukutin mutation causes Walker-Warburg syndrome in four Ashkenazi Jewish families. Prenat Diagn Jun;29(6): Driscoll, DA, Sehdev HM, Marchiano DA. Prenatal Screening for Genetic Conditions. Neoreviews. 2004;5:e Edvardson S, Shaag A, Zenvirt S, et al. Joubert syndrome 2 (JBTS2) in Ashkenazi Jews is associated with a TMEM216 mutation. Am J Hum Genet Jan;86(1):93-7. [PMID: ] 18. Ekstein J, Rubin BY, Anderson SL, et al. Mutation frequencies for glycogen storage disease Ia in the Ashkenazi Jewish population. Am J Med Genet Aug 30;129A(2): Elpeleg ON, Shaag A. The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-jewish patients. J Inherit Metab Dis Jun;22(4): [PMID: ] 20. Genetics Home Reference. Gaucher Disease. Last updated September Available at: http// in condition in gaucher-disease. 21. Genetics Home Reference. Glycogen Storage Disease Type 1A. Last updated September Available at: http// in condition in glycogen-storage-disease-type-i. 22. Glaser B, Blech I, Krakinovsky Y, et al. ABCC8 mutation allele frequency in the Ashkenazi Jewish population and risk of focal hyperinsulinemic hypoglycemia. Genet Med Oct;13(10): [PMID: ] 23. Glaser B. Familial Hyperinsulinism. GeneReviews. Last updated January 24, Available at: Hechtman P, Kaplan F, Bayleran J, et al. More than one mutant allele causes infantile Tay-Sachs disease in French-Canadians. Am J Hum Genet Nov;47(5): [PMID: ] 25. Hendrickson BC, Donohoe C, Akmaev VR, et al. Differences in SMN1 allele frequencies among ethnic groups within North America. J Med Genet Sept;46(9): [PMID ] 26. Jalas C, Anderson SL, Laufer T, Martimucci K, Bulanov A, Xie X, Ekstein J, Rubin BY. A founder mutation in the MPL gene causes congenital amegakaryocytic thrombocytopenia (CAMT) in the Ashkenazi Jewish population. Blood Cells Mol Dis Jun 15;47(1): [PMID: ] 27. Kaback MM, Desnick RJ. Hexosaminidase A Deficiency. GeneReviews. Last updated August 11, Available at: Kaul R, Gao GP, Matalon R, et al. Identification and expression of eight novel mutations among non-jewish patients with Canavan disease. Am J Hum Genet Jul;59(1): [PMID: ] 29. Keat BJB, Lentz J. Usher Syndrome Type I. GeneReviews. Last updated June 20, Available at: Lal A, Goldrich ML, Haines DA, Azimi M, Singer ST, Vichinsky EP. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med Feb 24;364(8): Lorey F, Arnopp J, et al. Distribution of hemoglobinopathy variants by ethnicity in a multiethnic state. Genetic Epidemiol. 1996;13: S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 7 of 8
8 32. Manzini MC, Gleason D, Chang BS, et al. Ethnically diverse causes of Walker-Warburg Syndrome (WWS): FCMD mutations are a more common cause of WWS outside of the Middle East. Hum Mutat. 2008;29(11): Matalon K, Matalon R. Canavan disease. Orphanet. Last updated December Available at: http// 34. McGovern MM, Schuchman EH. Acid Spingomyelinase Deficiency. GeneReviews. Last updated June 25, Available at: North KN, Ryan MM. Nemaline Myopathy. GeneReviews. Last updated September 18, Available at: Origa R, Moi P, Galanello R, Cao A. Alpha-Thalassemia. GeneReviews. Last updated December 29, Available at: Orphanet. Gaucher Disease. Last updated February Available at: http// 38. Orphanet. Walker-Warburg Syndrome. Last updated December Available at: Parisi M, Glass I. Joubert Syndrome and Related Disorders. GeneReviews. Last updated April 11, Available at: Pastores GM, Hughes DA. Gaucher Disease. GeneReviews. Last updated September 19, Available at: Population Surveys, Beta-Thalassemia Alleles. Available at: Accessed January 14, Quinonez SC, Thoene JG. Dihydrolipoamide Dehydrogenase Deficiency. GeneReviews. Last updated July 17,2014. Available at: Sanz M, German J. Bloom s Syndrome. GeneReviews. Last updated March 28, Available at: Schrijver I, Külm M, Gardner PI, Pergament EP, Fiddler MB. Comprehensive arrayed primer extension array for the detection of 59 sequence variants in 15 conditions prevalent among the (Ashkenazi) Jewish population. J Mol Diagn Apr;9(2): [PMID ] 45. Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease. J Inherit Metab Dis. 2007;30: Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornerich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat Nov;31(11): [PMID ] 47. Shaag A, Anikster Y, Christensen E, et al. The molecular basis of canavan (aspartoacylase deficiency) disease in European non-jewish patients. Am J Hum Genet Sep;57(3): [PMID: ] 48. Shohat M, Halpern G. Familial Dysautonomia. GeneReviews. Last updated June 1, Available at: Sistermans EA, de Coo RF, van Beerendonk HM, et al. Mutation detection in the aspartoacylase gene in 17 patients with Canavan disease: four new mutations in the non-jewish population. Eur J Hum Genet Jul;8(7): [PMID: ] 50. Strauss KA, Puffenberger EG, Morton DH. Maple Syrup Urine Disease. GeneReviews. Last updated May 9, Available at: Vanier MT, Ferlinz K, Rousson R, et al. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa. Hum Genet Oct;92(4): Vives-Corrons JL. Congenital amegakaryocytic thrombocytopenia. Orphanet. Last updated August Available at: http// php?lng=en&data_id=3053. Progenity is a CLIA-certified clinical laboratory and is accredited by the College of American Pathologists (CAP). The information contained in this document is provided as an educational service for healthcare providers and their patients Progenity, Inc. All rights reserved. Progenity is a registered service mark of Progenity, Inc. Preparent is a trademark of Progenity, Inc. CO REV S. State Road, Ann Arbor, MI Tel Fax progenity.com Page 8 of 8
PATIENT EDUCATION. carrier screening INFORMATION
PATIENT EDUCATION carrier screening INFORMATION carrier screening AT A GLANCE Why is carrier screening recommended? Carrier screening is one of many tests that can help provide information to you and your
More informationQHerit Expanded Carrier Screen
QHerit Expanded Carrier Screen Test Code: 94372 (X) Specimen Requirements: Preferred: 6 ml (4 ml minimum) room-temperature whole blood: 1.5 ml (1 ml minimum) in each of 4 lavender-top (EDTA) or yellow-top
More informationA Lawyer s Perspective on Genetic Screening Performed by Cryobanks
A Lawyer s Perspective on Genetic Screening Performed by Cryobanks As a lawyer practicing in the area of sperm bank litigation, I have, unfortunately, represented too many couples that conceived a child
More informationExomes and Beyond Addressing the Genome with OneSeq. Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA
Exomes and Beyond Addressing the Genome with OneSeq Madhuri Hegde, PhD, FACMG Emory University Emory Genetics Laboratory Atlanta, GA Technologies to Detect Various Types of Mutations RESOLUTION Targeted
More informationExpanded Carrier Screening: What s Best?
Expanded Carrier Screening: What s Best? James D Goldberg, MD September 17, 2017 Disclosures James D. Goldberg, M.D. Chief Medical Officer, Counsyl 3 Learning Objectives Guidelines Data Design Practice
More information23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert
Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro
More informationEVOLVE CARRIER GENETIC SCREENS. Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW.
EVOLVE CARRIER GENETIC SCREENS Better health for generations to come! Be Proactive. SCREEN TODAY. PROTECT TOMORROW. PROTECT THE HEALTH OF YOUR FUTURE CHILDREN BY KNOWING YOUR GENETIC RISKS, TODAY! Carrier
More informationBROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING.
BROADENING YOUR PATIENT S OPTIONS FOR GENETIC CARRIER SCREENING. The Inheritest SM Carrier Screen provides relevant genetic screening for many inherited diseases found throughout the pan-ethnic US population.
More information23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert
Table of contents Intended Use Important warnings and limitations Test performance User studies Specific test information 23andMe Personal Genome Service (PGS) Carrier Status Tests Package Insert For in-vitro
More informationShould Universal Carrier Screening be Universal?
Should Universal Carrier Screening be Universal? Disclosures Research funding from Natera Mary E Norton MD University of California, San Francisco Antepartum and Intrapartum Management June 15, 2017 Burden
More informationCystic fibrosis carrier screening in a North American population
American College of Medical Genetics and Genomics Original Research Article Cystic fibrosis carrier screening in a North American population Val V. Zvereff, MD,PhD 1, Hawazin Faruki, DrPh 1, Marcia Edwards,
More informationNutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:
NutraHacker Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d Instructions: In this report, NutraHacker examines single nucleotide polymorphisms that reveal carrier status
More informationSUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation
SUPPLEMENTARY INFORMATION Rare independent mutations in renal salt handling genes contribute to blood pressure variation Weizhen Ji, Jia Nee Foo, Brian J. O Roak, Hongyu Zhao, Martin G. Larson, David B.
More informationGenetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION
Carrier Screening and Diagnostic Testing for the Ashkenazi Jewish Population Genetic Testing FOR DISEASES OF INCREASED FREQUENCY IN THE ASHKENAZI JEWISH POPULATION Our Science. Your Care. An extensive
More informationRelated Policies None
Medical Policy MP 2.04.107 BCBSA Ref. Policy: 2.04.107 Last Review: 04/30/2018 Effective Date: 04/30/0218 Section: Medicine Related Policies None DISCLAIMER Our medical policies are designed for informational
More informationA Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples Sona Pekova, MD., PhD. Chambon Ltd., Laboratory for molecular diagnostics, Prague, Czech
More informationGenetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis
Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE OCTOBER 14, 2017 Appropriate.Safe.Affordable 2017 AIM Specialty Health 2068-1017
More informationCorporate Medical Policy
Corporate Medical Policy Carrier Screening for Genetic Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: carrier_screening_for_genetic_disease 12/2013 7/2017 7/2018 7/2017
More informationUW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA
Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s)
More informationBE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.
BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. THE LEADER IN FERTILITY & REPRODUCTIVE GENETIC SCREENING EvolveGene was founded by world leaders in preventive and personalized health care, with over 25 years
More informationResults Recipient Ordering Healthcare Professional Male Details Female Details
Results Recipient Ordering Healthcare Professional Male Details Details Report Date /2010 Attn: Jessica Jacobson, MD Counsyl, Inc. 2200 Bridge Parkway, Suite 103 Redwood City, CA 94065 Phone: 1-888-COUNSYL
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Wells JM, Farris RF, Gosdin TA, et al. Pulmonary
More informationAn Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers
An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers Theresa Steckel, RN, BSN Newborn Screening Quality Assurance and Education Coordinator Oklahoma State
More informationDonor xytex.com
Donor 5472 Information displayed in this profile is provided by the donor. Blank fields are intentional and indicate that the information is not available. xytex.com info@xytex.com 706-733-0130 General
More informationGENETIC TESTING AND COUNSELING FOR HERITABLE DISORDERS
Status Active Medical and Behavioral Health Policy Section: Laboratory Policy Number: VI-09 Effective Date: 03/17/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationIntron 1 IVS1+5G>T --- Greenberg et al, Exon II del2 Tsai et al, 2017 K42R 125A>G Spector et al, unpublished
Exon I M1V 1A>G Kolker et al, 2007 --- 11delG Spector & Sharer, unpublished S25L 74C>T Spector et al, unpublished --- 89/90 delc Mushimoto et al, 2011 88-91del4+IVS1 gtca Spector et al, unpublished Intron
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Approved By: CLINICAL MEDICAL POLICY Genetic Testing for Cystic Fibrosis MP-006-MD-DE Provider Notice Date: 11/1/2016 Original Effective Date: 12/1/2016 Annual Approval Date:
More informationCarrier Screening for Genetic Diseases
Medical Policy Manual Genetic Testing, Policy No. 81 Carrier Screening for Genetic Diseases Next Review: September 2018 Last Review: December 2017 Effective: January 1, 2018 IMPORTANT REMINDER Medical
More informationQUESTION. Personal Behavior History. Donor Genetic History. Donor Medical History. Family Medical History PERSONAL BEHAVIOR HISTORY. Never N/A.
Donor 4576 Medical Profile S Personal Behavior History Donor Genetic History Donor Medical History Family Medical History PERSONAL BEHAVIOR HISTORY Current alcohol use: If yes, oz./week and type of alcohol:
More informationForesight Carrier Screen
4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 09/20/2017 Date Received: 09/22/2017 Date Tested: 09/27/2017 Indication:
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT MARCH 13, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201208 MARCH 13, 2012 Updates to the 2012 Healthcare Common Coding System This bulletin updates information published by the Indiana Health Coverage Programs
More informationExon I M1V 1A>G Kolker et al, delG Spector & Sharer, unpublished /90 delc Mushimoto et al, 2011
Exon I M1V 1A>G Kolker et al, 2007 --- 11delG Spector & Sharer, unpublished 2006 --- 89/90 delc Mushimoto et al, 2011 Intron 1 IVS1+5G>T --- Greenberg et al, 1995 Exon II --- 109-110delCA Tsai et al, 2017
More informationGenetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis
Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 31, 2019 Appropriate.Safe.Affordable 2019 AIM Specialty Health 2068-0319 Table
More informationJOHN DOE JANE DOE. Reproductive Risk Summary. Counsyl Test Results Summary
Results Recipient University Medical Center 827 Attn: Dr. Paul Smith 123 Main Street Houston, TX 10231 Phone: (800) 555-1212 Fax: (800) 555-1212 NPI: 7834324983 Report Date: 09/09/2013 Female Ethnicity:
More informationPharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there
More informationMEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING. POLICY NUMBER: CATEGORY: Laboratory Test
MEDICAL POLICY SUBJECT: PRENATAL GENETIC TESTING PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationMedical Policy. Description/Scope. Position Statement
Subject: Document #: Current Effective Date: 03/29/2017 Status: Reviewed Last Review Date: 02/02/2017 Description/Scope This document addresses preconceptional or prenatal genetic testing on a parent or
More informationGenetic Carrier Screening
Genetic Carrier Screening Test Indications Carrier screening is a significant testing tool for inherited genetic conditions of prenatal care. The purpose of carrier screening is to identify couples at-risk
More informationGenomics in Women s Health: Changing the Diagnostic and Therapeutic Paradigm
Genomics in Women s Health: Changing the Diagnostic and Therapeutic Paradigm Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology Feinberg School of Medicine of Northwestern University
More informationSupplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM
Supplementary Data Supplementary Table e1. Clinical and genetic data on the 37 participants from the WUSM cohort. Supplementary Table e2. Specificity, sensitivity and unadjusted ORs for glioma in participants
More informationFabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.
Fabry Disease X-linked genetic, multi-organ disorder Fabry disease screening program in Hypertrophic p Cardiomyopathy: y preliminary results. Globotriaosylceramide, GL3 Brain -galactosidase A Eyes Lactosylceramide
More informationSupplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More information23andMe Reports GENETIC HEALTH RISK REPORTS. Increased risk for breast and ovarian cancer. function
1 23andMe Reports GENETIC HEALTH RISK REPORTS BRCA1/BRCA2 Late-Onset Alzheimer's Disease Parkinson's Disease Age-Related Macular Degeneration Alpha-1 Antitrypsin Deficiency Celiac Disease G6PD Deficiency
More informationTo test the possible source of the HBV infection outside the study family, we searched the Genbank
Supplementary Discussion The source of hepatitis B virus infection To test the possible source of the HBV infection outside the study family, we searched the Genbank and HBV Database (http://hbvdb.ibcp.fr),
More informationSupplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP
Supplemental Table 1. The list of variants with their respective scores for each variant classifier Gene DNA Protein Align-GVGD Polyphen-2 CADD MAPP Frequency Domain Mammals a 3 S/P b Mammals a 3 S/P b
More informationKalydeco. Kalydeco (ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Genetic Testing for Cystic Fibrosis Policy Number: MP-006-MD-DE Approved By: Medical Management Provider Notice Date: 04/15/2018; 11/01/2016 Issue Date: 05/15/2018
More informationClinical Policy Title: Genetic testing for maple syrup urine disease
Clinical Policy Title: Genetic testing for maple syrup urine disease Clinical Policy Number: 02.01.27 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018
More informationSupport. Overview. Auditory Dys-synchrony. Auditory Brainstem Response. Potential Causes
Potential Role of Genetic Testing in Auditory Neuropathy/Dys-synchrony Christina Runge-Samuelson, Ph.D., CCC-A Associate Professor Co-Director, Koss Cochlear Implant Program Department of tolaryngology
More informationGenetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome
Genetic Carrier Testing Cystic Fibrosis (CF) Spinal Muscular Atrophy (SMA) Fragile X Syndrome It s about knowing. Prenatal testing is not about telling you what s wrong, it s knowing that everything is
More informationCenters for Medicare and Medicaid Services
Centers for Medicare and Medicaid Services Clinical Laboratory Fee Schedule Annual Laboratory Public Meeting June 25, 2018 Anthony Sireci, MD, Msc Association for Molecular Pathology Outline Germline Procedures
More informationExpanded carrier screening in an infertile population: how often is clinical decision making affected?
American College of Medical Genetics and Genomics Original Research Article Expanded carrier screening in an infertile population: how often is clinical decision making affected? Jason M. Franasiak, MD
More informationForesight Carrier Screen
4915 25th Ave NE, Suite 204W Seattle, WA 98105 Phone: (206) 588-1484 Fax: (206) 466-4696 Sample Type: EDTA Blood Date of Collection: 08/17/2017 Date Received: 08/18/2017 Date Tested: 08/24/2017 Indication:
More informationCMS will not implement the new tier codes for Medicare/Medicaid claims for calendar year 2012.
January 1, 2012 Re: 2012 AMA CPT Code Changes Dear Valued Client: The American Medical Association (AMA) has made Current Procedural Terminology (CPT) code changes to the 2012 edition of the CPT coding
More informationCHRONIC MYELOGENOUS LEUKEMIA
CHRONIC MYELOGENOUS LEUKEMIA SHUFFLING THE GENETIC DECK IN CML 9 9 (q+) 22 Ph (22q-) bcr bcr-abl abl Fusion protein causes cancer GLEEVEC AND BCR-ABL FUSION PROTEIN GENETIC MEDICINE A. Genetic diseases
More informationTEST INFORMATION Test: CarrierMap GEN (Genotyping) Panel: CarrierMap Expanded Diseases Tested: 311 Genes Tested: 299 Mutations Tested: 2647
Ordering Practice Jane Smith John Smith Practice Code: 675 Miller MD 374 Broadway New York, NY 10000 Physician: Dr. Frank Miller Report Generated: 2016-02-03 DOB: 1973-02-19 Gender: Female Ethnicity: European
More informationERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative
ORIGINAL ARTICLE ERCP findings in idiopathic pancreatitis: patients who are cystic fibrosis gene positive and negative Waleed M. Alazmi, MD, Evan L. Fogel, MD, Suzette Schmidt, RN, James L. Watkins, MD,
More informationSupplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
More informationLab Prior Authorization
Lab Prior Authorization On July 22, 2015, BlueCross BlueShield of South Carolina announced that it will partner with Avalon Healthcare Solutions (Avalon) to administer a comprehensive suite of laboratory
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationThe role of E148Q in FMF. Elon Pras Institute of Human Genetics Sheba Medical Center
The role of E148Q in FMF Elon Pras Institute of Human Genetics Sheba Medical Center Familial Mediterranean Fever (FMF) Acute attacks of fever accompanied by: Peritonitis Pleuritis Arthritis Erysipelas
More informationBRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups
BRCA Mutations and Outcome in Epithelial Ovarian Cancer: Experience in Ethnically Diverse Groups Tamar Safra, MD, Barliz Waissengrin, MD, Lucia Borgato, MD, Moshe Leshno, MD, Elsa Reich, MD, Julia Smith,
More informationDonor xytex.com
Donor 5472 Information displayed in this profile is provided by the donor. Blank fields are intentional and indicate that the information is not available. xytex.com info@xytex.com 706-733-0130 General
More informationGenetic evaluation procedures at sperm banks in the United States
Genetic evaluation procedures at sperm banks in the United States Lauren Isley, M.S., C.G.C. a and Pamela Callum, M.S., C.G.C. a,b a Assisted Reproductive Technology and Infertility Special Interest Group,
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Alpha Thalassemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alpha_thalassemia 9/2013 7/2017 7/2018 7/2017 Description
More informationORIGINAL INVESTIGATION. Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population
ORIGINAL INVESTIGATION Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population The First 1000 Cases at New York University Medical Center, New York,
More informationPreparent Carrier Screen Global Panel Disorders
Preparent Screen Global Panel Disorders See next section for Global+ Panel disorders. Disorder Gene Variants Ethnicity 17-alpha-hydroxylase deficiency CYP17A1 1118A>T, 160_162delTTC 17-beta-hydroxysteroid
More informationhelpful guide Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X
A helpful guide to Carrier Testing for Common Genetic Diseases Hemoglobinopathies Cystic Fibrosis Spinal Muscular Atrophy Fragile X Joseph Adashek, M.D., FACOG Paul T. Wilkes, M.D., FACOG Van R. Bohman,
More informationSequencing in Newborn Screening Introduction and Background
Sequencing in Newborn Screening Introduction and Background Suzanne Cordovado, PhD Newborn Screening and Molecular Biology Branch Division of Laboratory Sciences Centers for Disease Control and Prevention
More informationCarrier Screening for Genetic Diseases. (204107) (Formerly Carrier Testing for Genetic Diseases)
Protocol Carrier Screening for Genetic Diseases (204107) (Formerly Carrier Testing for Genetic Diseases) Medical Benefit Effective Date: 04/01/18 Next Review Date: 11/18 Preauthorization Yes Review Dates:
More informationVertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son
More informationResult Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: RAD51C Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationmodified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
More informationORIGINAL RESEARCH ARTICLE
American College of Medical Genetics and Genomics Open An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals
More informationVariant annotation Extracted variants listed in dbsnp, OMIM, ClinVar, and HGMD 2434 variants
Whole Genome Sequencing and Variant Calling Whole genome sequencing and variant calling of 128 healthy Ashkenazi Jews carried out by Complete Genomics. Merged 128 genomes using CGA tools, obtained 273250
More informationGENETIC SCREENING. Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES DISCLOSURE
GENETIC SCREENING Prof Dr Karen Sermon, MD, PhD LEARNING OBJECTIVES At the conclusion of this presentation, participants should be able to answer the following questions: What is (genetic) screening? Why
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More informationCPTR title slide. A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance
CPTR title slide A Standardized System for Grading Mutations in Mycobacterium tuberculosis for Association with Drug Resistance PAOLO MIOTTO CPTR 2017 Workshop, March 20 23 The Need A lack of user-friendly
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationarticle May/June 2001 Vol. 3 No. 3
article May/June 2001 Vol. 3 No. 3 Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded, pan-ethnic mutation panel Ruth A. Heim, PhD, Elaine A. Sugarman,
More informationFAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM
THE ESSENTIAL PANEL There are many unknowns in life. FAMILY PLANNING DOESN T HAVE TO BE ONE OF THEM PLANNING FOR A FAMILY IS A BIG DECISION TAKE STEPS TOWARD A HEALTHY FUTURE WITH NXGEN GENETIC CARRIER
More informationSymdeko. Symdeko (tezacaftor and ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.10 Subject: Symdeko Page: 1 of 5 Last Review Date: June 22, 2018 Symdeko Description Symdeko (tezacaftor
More informationSusanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience
Susanne Schnittger Workflow of molecular investigations in JAK2negative MPNs the Munich experience Cohort single centre experience to apply new markers in a daily diagnostic work flow total: 20,547 cases
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Supplemental Methods Phenotype Prediction Analyses In order to assess the phylogenetic properties of nssnvs, sequence conservation analysis was conducted using
More informationGenetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri
Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri By Bria Collette Kettle Submitted to the graduate degree program in
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationIVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER
IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight
More informationVirological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
More informationHCV NS3 Protease Drug Resistance
test code: cpt code: 10000 87902 category: Infectious Disease HCV genotypes 1a CODON Simeprevir 1a Boceprevir 1a Telaprevir 1a Paritaprevir 1a Grazoprevir 1a V36A Comment R 3 R 10, 11 R 16 S 24 V36C V36G
More informationReproductive Medicine & Infertility Associates. I. Reproductive Medicine & Infertility Associates (RMIA)
Reproductive Medicine & Infertility Associates In compliance with the Federal Consumer Credit Protection Act, we wish to notify you of our policies regarding the payment of statements for services rendered
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationHCV NS3 Protease Drug Resistance
test code: cpt code: 10000 87902 category: Infectious Disease HCV genotype 1a CODON Glecaprevir 1a Grazoprevir 1a Paritaprevir 1a Simeprevir 1a Voxilaprevir 1a V36A S 13 R 10 Comment V36C V36G V36I V36L
More informationResult Navigator. Positive Test Result: CDH1. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: CDH1 Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationgenetic carrier screening for cystic fibrosis results you Can trust
genetic carrier screening for cystic fibrosis results you Can trust Cystic Fibrosis Carrier Screening Why Carrier Screening for Cystic Fibrosis Is Important? Carrier screening tests help identify individuals
More informationBE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW.
BE PROACTIVE. SCREEN TODAY. PROTECT TOMORROW. THE LEADER IN FERTILITY & REPRODUCTIVE GENETIC SCREENING EvolveGene was founded by world leaders in preventive and personalized healthcare, with over 25 years
More informationTECHNICAL NOTICE. The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays
TECHNICAL NOTICE The CPT coding in this notice is effective January 1, 2013 and replaces the coding currently in use for these assays December 2012 The notation (MAAA) indicates "Multianalyte Assay with
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: April 15, 2018 Related Policies: 2.04.59 Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies Genetic
More informationDisclosures. Update on Medical Genetics for Family Practitioners. Objectives. Genetic Testing. Types of Genetic Tests. Dogma of Genetics 08/05/2018
Update on Medical Genetics for Family Practitioners Genetic Testing, Newborn Screening, and Direct to Consumer Testing Sandhya Parkash, MD, FRCPC, FCCMG Maritime Medical Genetics Service, IWK Health Centre
More information